Coherus Oncology Inc (CHRS)

EBITDA

-$30.16M

Quarterly · Period ending: · USD

CHRS logo

CHRS EBITDA

Latest reported-$30.16M
CHRS Quarterly EBITDA (-$9.34M → -$30.16M)
High-resolution chart · PNG

CHRS ebitda history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc EBITDA — Quarterly (USD)
Period endingEBITDA (USD)
-30,162,000
-33,868,000
-43,202,000
-41,226,000
-41,569,000
-44,202,000
-44,317,000
-3,840,000
-6,400,000
-63,411,000
-67,971,000
-28,854,000
-32,046,000
-65,068,000
-48,435,000
-78,115,000
-42,683,000
-86,348,000
-38,507,000
-31,865,000
-23,276,000
-166,450,000
17,271,000
34,465,000
66,481,000
41,543,000
46,809,000
53,198,000
28,167,000
-15,097,000
-59,549,000
-55,601,000
-40,366,000
-40,972,000
-45,743,000
-55,845,000
-52,180,000
-71,581,000
-72,778,000
87,017,000
-62,736,000
-63,635,000
-51,224,000
-70,816,000
-58,634,000
-40,607,000
-24,991,000
-7,721,000
-23,781,000
-22,313,000
-11,182,000
-19,380,000
-9,185,000
-9,343,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.